449804-09-5

Usage

Molecular Weight

390.11 g/mol

Functional Groups

Fluorine-substituted alcohol group
Phenyl ring
Boron-containing side chain (1,3,2-dioxaborolane)

Structural Features

Hexafluoro substitution on the propanol group
Tetramethyl substitution on the boron-containing side chain

Potential Applications

Organic synthesis
Chemical research
Building block for new chemicals or materials

Reactivity

May undergo reactions involving the alcohol group, phenyl ring, or boron-containing side chain

Stability

Requires further investigation to determine stability under various conditions

Solubility

Likely soluble in organic solvents, but specific solubility properties would require further investigation

Safety and Handling

Potential hazards and safety precautions would require further investigation

Environmental Impact

Environmental fate and impact would require further investigation and research

Upstream product

• 2402-72-4 2-(4-bromophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 73183-34-3 bis(pinacol)diborane 
• 1214788-34-7 1,1,1,3,3,3-hexafluoro-2-(4-iodophenyl)propan-2-ol 
• 722-92-9 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Downstream Products

• 449803-28-5 5-methyl-4-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-isoxazole-3-carboxylic acid ethyl ester 
• 1361216-08-1 1,1,1,3,3,3-hexafluoro-2-(4'-(phenylsulfonyl)-4-biphenylyl)-2-propanol 
• 449803-22-9 5-methyl-4-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-isoxazole-3-carboxylic acid methoxy-methyl-amide 
• 449803-57-0 5-methyl-4-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-isoxazole-3-carboxylic acid 
• 449803-92-3 2-[4-(3-amino-5-methyl-isoxazol-4-yl)-phenyl]-1,1,1,3,3,3-hexafluoro-propan-2-ol 

Relevant academic research and scientific papers

BICYCLIC ROR-GAMMA MODULATORS

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

SPIROCYCLIC ROR-GAMMA MODULATORS

Described herein are retinoic acid related-related orphan nuclear receptor (ROR) modulators and methods of utilizing ROR-gamma modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

Modulators of the nuclear hormone receptor ROR

The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ, of formula with the variable atoms as defined herein and R1 comprising a hydroxyl- or alkoxyl-substituted fluoroalkyl group. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided.

Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational Analysis

The glucokinase-glucokinase regulatory protein (GK-GKRP) complex plays an important role in controlling glucose homeostasis in the liver. We have recently disclosed a series of arylpiperazines as in vitro and in vivo disruptors of the GK-GKRP complex with

SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

Design and synthesis of heterocyclic malonyl-CoA decarboxylase inhibitors

We have previously reported the discovery of small molecule inhibitors of malonyl-CoA decarboxylase (MCD) as novel metabolic modulators, which inhibited fatty acid oxidation and consequently increased the glucose oxidation rates in the isolated working ra